Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Asenapine Sublingual Tablets vs SAPHRIS in Schizophrenia Patients
NCT02072954Phase 3Completed
- Sponsor
- Amneal Pharmaceuticals, Inc.
- Start
- Nov 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of asenapine in schizophrenia, sponsored by Amneal Pharmaceuticals, Inc.. Started Nov 2013; status: completed.
02
Drugs
asenapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02072954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072954.